Date:11/4/2011

icroRNAs as biomarkers lies in their high tissue specificity, and their exceptional stability in the most routine preservation methods for biopsies, including Formalin Fixed Paraffin Embedded (FFPE) block tissue and fine needle aspirate (FNA) cell blocks. It has been suggested that their small size (19 to 21 nucleotides) enables them to remain intact in FFPE blocks, as opposed to messenger RNA (mRNA), which tends to degrade rapidly. In addition, early preclinical data has shown that by controlling the levels of specific microRNAs, cancer cell growth may be reduced.  To learn more about microRNAs, please visit www.rosettagenomics.com .About Rosetta GenomicsRosetta Genomics develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. The Company's miRview product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  

Forward-Looking StatementsVarious statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the potential of microRNAs in the diagnosis and treatment of disease, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach t
'/>"/>

SOURCE Rosetta Genomics Copyright©2010 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
2. Berkeley Lab scientists develop new tool for the study of spatial patterns in living cells
3. CU-Boulder python study may have implications for human heart health
4. Study offers clues as to why some patients get infections from cardiac implants
5. Study Hints at Possible Therapeutic Strategy to Combat Premature Birth
6. Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease
7. EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
8. HABIT Study Highlights Home BNP Testing May Allow for Earlier Interventions and Better Management of Heart Failure Patient
9. International Study Confirms CNSystems-Technology
10. Childrens Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)
11. Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Menieres Disease at International Conference